When working with naltrexone, an oral or injectable medication that blocks opioid receptors. Also known as Revia or Vivitrol, it is used to treat alcohol dependence and prevent opioid relapse.
Opioid antagonist refers to drugs that bind to opioid receptors without activating them, effectively stopping the effects of opioids. Naltrexone belongs to this class and works by occupying the mu‑opiod receptors in the brain. By doing so, it blocks both the euphoric high from opioid use and the craving signals that drive alcohol consumption. This dual action makes it a valuable tool in both addiction treatment and overdose prevention.
Alcohol dependence is a chronic condition where a person cannot control drinking despite negative consequences. In people with this condition, naltrexone reduces the rewarding feeling of alcohol, which lowers cravings and helps maintain abstinence. Clinical trials show a 30‑40% reduction in heavy‑drinking days when the drug is combined with counseling. The medication is usually started once the patient is sober for at least a week, then taken daily at a dose of 50 mg.
First, dosing matters. The oral form comes in 50 mg tablets taken once daily. The injectable version, Vivitrol, is a 380 mg depot shot given once a month. The monthly shot ensures steady blood levels and eliminates the need for daily pills, which many patients prefer. However, the injection requires a healthcare professional to administer it, and the cost is higher.
Second, side effects are usually mild but worth knowing. Common complaints include nausea, headache, dizziness, and fatigue. These tend to fade after the first few days as the body adjusts. Rarely, severe liver injury can occur; therefore, baseline liver tests are recommended before starting therapy and periodically afterward.
Third, drug interactions can be tricky. Naltrexone should not be taken with opioid painkillers, because it will block their pain‑relieving effect and could trigger withdrawal symptoms. It also interacts with certain hepatitis C treatments and high‑dose benzodiazepines, so a full medication review is essential.
Fourth, patient selection is crucial. The medication works best for people motivated to stay sober and who have a supportive environment. Those with active opioid use, uncontrolled liver disease, or a history of severe psychiatric illness may need alternative approaches.
Finally, real‑world success often hinges on combining naltrexone with behavioral therapy. Cognitive‑behavioral therapy, 12‑step programs, or motivational interviewing provide the coping skills that medication alone cannot deliver. When both pieces are in place, relapse rates drop dramatically.
Beyond the basics, researchers are exploring new naltrexone formulations, such as low‑dose oral regimens for binge‑eating disorder and extended‑release implants for long‑term opioid relapse prevention. These studies suggest the drug’s utility may expand further, but current guidelines still focus on alcohol dependence and opioid use disorder.
If you’re considering naltrexone, the first step is a thorough assessment with a healthcare provider who can evaluate liver function, current medications, and your readiness to change. Starting low, monitoring side effects, and staying in touch with a support network are the best ways to make the treatment work.
Below you’ll find a curated collection of articles that dive deeper into specific scenarios—managing drug interactions, comparing oral versus injectable options, handling side effects, and more. Whether you’re a patient, caregiver, or clinician, these resources will give you practical insights to get the most out of naltrexone therapy.
A side‑by‑side look at Naltrexone, its mechanism, dosage, and how it stacks up against Disulfiram, Acamprosate, Naloxone and Buprenorphine for alcohol and opioid dependence.
full article
